Objective:To explore the therapeutic effect of bicalutamide on prostate cancer.Methods:Ninety-five patients with prostate cancer in the First People's Hospital of Jiande were selected from January 2014 to January 2019.All 95 patients received blood samples before treatment were selected as case group, and 85 healthy subjects were selected as control group.The clinical symptoms of the patients before treatment and after treatment with bicalutamide for 3, 6, 9, 12 months were recorded.The blood samples were taken as the treatment group at 12 months after treatment.The effect of bicalutamide on the expression of miRNA-125b and miRNA-21 in serum of patients with prostate cancer was detected by RT-PCR.Results:After treatment, the prostate volume and serum prostate specific antigen (PSA) expression were significantly reduced(3 months after treatment compared with before treatment, prostate volume: t=6.22, P=0.00; PSA: t=5.14, P=0.00; 6 months after treatment compared with before treatment, prostate volume: t=8.32, P=0.00; PSA: t=4.11, P=0.00; 12 months after treatment compared with before treatment, prostate volume: t=10.14, P=0.00; PSA: t=9.25, P=0.00; 6 months after treatment compared with 3 months after treatment, prostate volume: t=3.82, P=0.00; PSA: t=6.23, P=0.00; effective rate: χ 2=6.38, P=0.00.One year after treatment compared with 3 months after treatment, prostate volume: t=4.16, P=0.00; PSA: t=5.77, P=0.00; effective rate: χ 2=5.74, P=0.00.One year after treatment compared with 6 months after treatment, the prostate volume: t=8.11, P=0.00; PSA: t=4.92, P=0.00; effective rate: χ 2=4.44, P=0.00). And with the extension of treatment time, the treatment effect was significantly enhanced.RT-PCR results showed that compared with the control group, the expression levels of miRNA-125b and miRNA-21 in the case group were significantly increased( t=6.22, 6.88, P=0.01, 0.00). After treatment with bicalutamide, the levels of miRNA-125b and miRNA-21 in serum of prostate cancer patients were significantly reduced. Conclusion:Bicalutamide can reduce the pain and increase the efficacy of prostate cancer patients; bicalutamide can reduce the expression of miRNA-125b and miRNA-21 in serum of patients with prostate cancer.

Objective To establish a novel method using a nano microfluidic chip to detect circulating tumor cells (CTCs) in peripheral blood in gallbladder carcinoma,and to study the relationship between CTCs with clinicopathology and prognosis in these patients.Methods The peripheral blood samples of 51 patients with gallbladder carcinoma were collected from June 2014 to January 2017.The CTCs from peripheral blood samples were detected by a novel nano microfluidic chip.This study aimed to study the correlation between CTCs with the clinical and pathological features.The significance of CTCs on prognosis in patients with gallbladder carcinoma was also analyzed.Results The positive rate of CTCs in the peripheral blood of gallbladder carcinoma patients was 43.1％ (22/51).There were significant correlations between CTCs with liver metastasis (P ＜ 0.05) and Nevin staging (P ＜ 0.05).The 1-and 2-year overall survival (OS) in patients with CTCs were 70.7％ and 35.3％,and the 1-and 2-year OS in patients without CTCs were 92.0％ and 56.1％.There was a significant difference in the 2-year OS (P ＜ 0.05) but no significant difference in the 1-year OS between the 2 groups of patients (P ＞ 0.05).Conclusions Peripheral blood CTCs in patients with gallbladder carcinoma were efficaciously detected by a novel nano microfluidic chip.Peripheral blood CTCs was closely related to the Nevin staging and liver metastasis.CTCs could serve as a potential prognostic indicator in patients with gallbladder carcinoma.